

29 MAYO-2 JUNIO | CHICAGO

2026 **ASCO**[®]
ANNUAL MEETING

SPOT LIGHTS 2026

FARMACIA HOSPITALARIA AL DÍA EN ONCOLOGÍA

NATALEE: Impacto de la Genómica

Una iniciativa científica de:




Con el patrocinio de:

REGENERON[®]

- Análisis del valor pronóstico y predictivo de la expresión génica basal en el estudio fase III NATALEE.
- **Población:** Cáncer de mama precoz HR+/HER2- (Estadios II/III)
- **Tratamiento:** Ribociclib (400 mg) + Inhibidor de Aromatasa (IA)

NATALEE study design




ctDNA/RNA, circulating tumor DNA/RNA; EBC, early breast cancer; ET, endocrine therapy; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; iDFS, invasive disease-free survival; NSAI, nonsteroidal aromatase inhibitor; OS, overall survival; PK, pharmacokinetics; PRO, patient-reported outcome; pt, patient; R, randomized; STEEP, Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials.

^a Enrollment of patients with stage II disease was capped at 40%. ^b 5101 patients were randomized from January 10, 2019, to April 20, 2021. ^c Open-label design. ^d Per investigator choice. Fasching PA et al. ESMO 2024. Oral LBA13.

Eficacia Consistente por Subtipos PAM50

- Surgical samples from 3022 patients in NATALEE (N = 5101) were profiled for PAM50-based intrinsic subtype with a NanoString BC360 panel of 758 genes related to breast cancer, immune response, and the tumor microenvironment and 46 gene signatures
- Ribociclib demuestra beneficio clínico en todos los subtipos intrínsecos analizados, independientemente de la agresividad biológica basal.

Ribociclib treatment benefit was seen across all PAM50-based intrinsic subtypes




- Across treatment arms, PAM50 subtypes were strongly prognostic (hazard ratio vs luminal A: luminal B, 1.39; HER2-enriched, 2.62; basal-like, 3.92^d)
- No significant interaction between subtype and treatment was observed ($P = .34^c$)

El beneficio se mantiene estable sin diferencia significativa entre tratamiento y subtipo ($P = 0.34$).


- Se observa una tendencia a mayor beneficio en pacientes con altas puntuaciones de riesgo genómico y proliferación.
- La alta expresión de **CEACAM6** y la baja expresión de **GATA3** se identifican como potenciales biomarcadores de respuesta.

Higher expression of CEACAM6 was associated with increased ribociclib benefit




NSAI, nonsteroidal aromatase inhibitor; RIB, ribociclib.

Lower expression of GATA3 was associated with increased ribociclib benefit



- Estos hallazgos validan el uso de Ribociclib en toda la población elegible, reforzando su valor terapéutico independientemente del subtipo molecular.



29 MAYO-2 JUNIO | CHICAGO

2026 **ASCO**[®]
ANNUAL MEETING

SPOT LIGHTS 2026

FARMACIA HOSPITALARIA AL DÍA EN ONCOLOGÍA

MUCHAS GRACIAS

Una iniciativa científica de:



Con el patrocinio de:

REGENERON[®]